Covid vaccine maker passes its remuneration policy but suffers sizeable rebellion
AstraZeneca investors narrowly approved pay package proposals for its chief executive, Pascal Soriot, after nearly 40%voted against the policy, which could hand him payand perks of up to £17.8m for 2021.
At the company’s annual meeting in Cambridge, the Anglo-Swedish drugmaker managed to pass its remuneration policy, which required support from shareholders holding more than 50% of the firm’s stock, but suffered a sizeable rebellion, as investors owning 39.8% of the shares opposed it. The rest voted in support of the policy.